Praluent-treated patients started the trial on 75 mg every 2 weeks, and 2,615 of them switched to 150 mg every 2 weeks because their LDL-C levels remained above 50 mg/dL.

Sanofi and Regeneron have scored a major victory in their fight with Amgen in the market for cardiovascular drugs, after releasing data showing their Praluent injection reduces risk of ...